Today: 19 May 2026
Browse Category

NASDAQ:ITCI 27 June 2025

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

The FDA approved Abeona’s Zevaskyn, the first cell-based gene therapy for RDEB, in April 2025, with launch set for Q3 at $3.1 million. Vertex’s CRISPR therapy Casgevy generated $2 million in Q3 2024. Novo Holdings acquired Catalent for $16.5 billion in January 2025 to secure GLP-1 drug manufacturing. Johnson & Johnson bought Intra-Cellular Therapies for $14.6 billion, expanding its neuroscience portfolio.
27 June 2025
···········

Stock Market Today

  • New 2024 Legislation Challenges Traditional 6% Real Estate Commissions
    May 19, 2026, 6:12 AM EDT. In 2024, new legislation aims to disrupt the standard 6% commission model in real estate sales. This change targets commissions on high-value properties like a $1 million Maui home. Sellers may see reduced agent fees as the law encourages more competitive pricing structures, potentially saving thousands of dollars. The shift reflects increasing pressure on traditional real estate agents to adjust their commission rates in a changing market landscape.

Latest articles

Hesai Stock Rises Before the Bell as Mercedes Lidar Deal Meets Q1 Profit

Hesai Stock Rises Before the Bell as Mercedes Lidar Deal Meets Q1 Profit

19 May 2026
Hesai Group shares rose 2.68% to $22.60 in U.S. premarket trading after reporting a first-quarter profit and confirming it will supply lidar sensors for Mercedes-Benz Level 3 autonomous models. The company shipped 471,723 lidar units, up 140.9% year-on-year, and posted revenue of RMB680.6 million ($98.7 million). Net income reached RMB18.3 million, reversing a loss from a year earlier.
Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open

Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open

19 May 2026
Virax Biolabs shares surged 53.1% Monday to $0.2350 and climbed another 17.1% in early Tuesday premarket trading, hitting $0.2751. The rally followed a paid RedChip TV appearance and a May 15 ownership filing showing Armistice Capital with a 4.99% stake. No new clinical or product updates were posted. Trading volume Monday reached about 765.2 million shares.
Amesite Shares Rise Premarket After NurseMagic Signs Largest Client

Amesite Shares Rise Premarket After NurseMagic Signs Largest Client

19 May 2026
Amesite Inc. shares surged 218% to $2.50 in premarket trading after announcing its largest NurseMagic deployment with a 2,700-patient home-care client. The company disclosed $83,332 in quarterly revenue and a $678,061 net loss, with cash at $740,711 before a $2.2 million April financing. Amesite did not reveal the new contract’s value or customer name. Its latest filing cited “substantial doubt” about ongoing operations.

Popular

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.
Go toTop